[go: up one dir, main page]

SI3027642T1 - Konstrukti dejavnika diferenciacije rasti 15 (GDF-15) - Google Patents

Konstrukti dejavnika diferenciacije rasti 15 (GDF-15)

Info

Publication number
SI3027642T1
SI3027642T1 SI201431664T SI201431664T SI3027642T1 SI 3027642 T1 SI3027642 T1 SI 3027642T1 SI 201431664 T SI201431664 T SI 201431664T SI 201431664 T SI201431664 T SI 201431664T SI 3027642 T1 SI3027642 T1 SI 3027642T1
Authority
SI
Slovenia
Prior art keywords
gdf
constructs
differentiation factor
growth differentiation
growth
Prior art date
Application number
SI201431664T
Other languages
English (en)
Inventor
Yumei Xiong
Yi Zhang
Jackie Z. Sheng
Agnes Eva Hamburger
Murielle Veniant-Ellison
Grant Shimamoto
Xiaoshan Min
Zhulun Wang
Jie Tang
Gunasekaran Kannan
Marissa Mock
Kenneth Walker
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3027642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI3027642T1 publication Critical patent/SI3027642T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201431664T 2013-07-31 2014-07-31 Konstrukti dejavnika diferenciacije rasti 15 (GDF-15) SI3027642T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31
EP14752711.3A EP3027642B1 (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs
PCT/US2014/049254 WO2015017710A1 (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Publications (1)

Publication Number Publication Date
SI3027642T1 true SI3027642T1 (sl) 2020-11-30

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431664T SI3027642T1 (sl) 2013-07-31 2014-07-31 Konstrukti dejavnika diferenciacije rasti 15 (GDF-15)

Country Status (35)

Country Link
US (4) US9862752B2 (sl)
EP (2) EP3763734A1 (sl)
JP (5) JP6509852B2 (sl)
KR (3) KR20240000642A (sl)
CN (2) CN113527512A (sl)
AP (1) AP2016009011A0 (sl)
AR (1) AR097181A1 (sl)
AU (1) AU2014296107B2 (sl)
BR (1) BR112016002213A2 (sl)
CA (1) CA2918624C (sl)
CL (1) CL2016000249A1 (sl)
CR (1) CR20160097A (sl)
CY (1) CY1123836T1 (sl)
DK (1) DK3027642T3 (sl)
EA (2) EA037355B1 (sl)
ES (1) ES2828670T3 (sl)
HU (1) HUE050630T2 (sl)
IL (1) IL243749B (sl)
JO (1) JO3566B1 (sl)
LT (1) LT3027642T (sl)
MA (1) MA38873B1 (sl)
MX (2) MX369152B (sl)
NZ (2) NZ717030A (sl)
PE (1) PE20160189A1 (sl)
PH (1) PH12016500208A1 (sl)
PL (1) PL3027642T3 (sl)
PT (1) PT3027642T (sl)
SG (1) SG11201600713RA (sl)
SI (1) SI3027642T1 (sl)
TN (1) TN2016000035A1 (sl)
TW (1) TWI648401B (sl)
UA (1) UA116665C2 (sl)
UY (1) UY35686A (sl)
WO (1) WO2015017710A1 (sl)
ZA (1) ZA201600523B (sl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
SI3027642T1 (sl) * 2013-07-31 2020-11-30 Amgen Inc. Konstrukti dejavnika diferenciacije rasti 15 (GDF-15)
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) * 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
BR112016029848A2 (pt) 2014-06-24 2017-10-24 Novo Nordisk As proteínas de fusão mic-1 e utilizações das mesmas
EA035581B1 (ru) 2014-07-30 2020-07-10 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы применения для лечения метаболических расстройств
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201741333A (zh) 2016-05-24 2017-12-01 諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
SG11202012993SA (en) * 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
JP7539902B2 (ja) 2018-10-22 2024-08-26 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
JP2022530216A (ja) * 2019-04-23 2022-06-28 エルジー・ケム・リミテッド 免疫グロブリンのＦｃ領域およびＧＤＦ１５を含む融合ポリペプチド
KR20220016139A (ko) * 2019-05-30 2022-02-08 암젠 인크 항체 이량체화를 유도하기 위한 경첩 영역 조작
CA3142440A1 (en) 2019-06-07 2020-12-10 Amgen Inc. Bispecific binding constructs
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
MX2022006173A (es) * 2019-11-26 2022-06-14 Yuhan Corp Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma.
MX2022006634A (es) * 2019-12-11 2022-07-04 Lg Chemical Ltd Polipeptido de fusion que comprende gdf15 y region de polipeptido capaz de experimentar o-glicosilacion.
JP2023507846A (ja) 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CA3172548A1 (en) * 2020-02-20 2021-08-26 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
AU2021228729A1 (en) 2020-02-28 2022-09-22 Kallyope, Inc. GPR40 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
EP4237438A4 (en) 2020-10-27 2024-11-27 Beijing QL Biopharmaceutical Co., Ltd. GDF15 FUSION PROTEINS AND THEIR USE
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US20240343770A1 (en) * 2021-08-24 2024-10-17 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
KR20230044130A (ko) * 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114835810B (zh) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用
WO2025024658A1 (en) * 2023-07-27 2025-01-30 Binacea Pharma, Inc. Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
WO2025106761A1 (en) 2023-11-17 2025-05-22 Eli Lilly And Company Compounds for the treatment of diabetes or obesity

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
CZ20012406A3 (cs) * 1999-01-07 2002-03-13 Lexigen Pharmaceuticals, Corp. Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MXPA03005036A (es) * 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
KR20060026860A (ko) * 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
ES2426169T3 (es) * 2003-11-13 2013-10-21 Hanmi Science Co., Ltd. Composición farmacéutica que comprende una región Fc de inmunoglobulina como portador
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006020884A2 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
US20070161081A1 (en) * 2005-11-10 2007-07-12 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
JP2010500876A (ja) * 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
EP2187933A4 (en) 2007-08-16 2010-12-08 St Vincents Hosp Sydney MEANS AND METHOD FOR MODULATING THE ACTIVITY OF MACROPHAGES-INHIBITING CYTOKINE (MIC-1)
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
WO2011063348A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
CA2782814A1 (en) 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2534921T3 (es) 2010-08-26 2015-04-30 F. Hoffmann-La Roche Ag Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
CN108341868B (zh) * 2010-11-05 2022-06-07 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2012142515A2 (en) * 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2012355415B2 (en) * 2011-12-20 2017-07-06 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
ES2740749T3 (es) * 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
DK2934584T3 (da) 2012-12-21 2020-05-18 Aveo Pharmaceuticals Inc Anti-gdf15-antistoffer
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
SI3027642T1 (sl) 2013-07-31 2020-11-30 Amgen Inc. Konstrukti dejavnika diferenciacije rasti 15 (GDF-15)
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
WO2015200080A1 (en) 2014-06-23 2015-12-30 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
BR112016029848A2 (pt) 2014-06-24 2017-10-24 Novo Nordisk As proteínas de fusão mic-1 e utilizações das mesmas
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201741333A (zh) 2016-05-24 2017-12-01 諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
BR112016002213A2 (pt) 2017-08-29
AU2014296107A1 (en) 2016-02-04
ES2828670T3 (es) 2021-05-27
TW201602345A (zh) 2016-01-16
JO3566B1 (ar) 2020-07-05
JP6509852B2 (ja) 2019-05-08
CL2016000249A1 (es) 2016-07-22
NZ717030A (en) 2022-04-29
IL243749B (en) 2018-06-28
JP6877478B2 (ja) 2021-05-26
JP2025024032A (ja) 2025-02-19
SG11201600713RA (en) 2016-02-26
AU2014296107B2 (en) 2018-07-26
US20240368236A1 (en) 2024-11-07
US10894814B2 (en) 2021-01-19
CN105980400B (zh) 2021-05-07
MA38873B1 (fr) 2018-11-30
PH12016500208B1 (en) 2016-04-25
TN2016000035A1 (en) 2017-07-05
MA38873A1 (fr) 2017-09-29
EP3027642A1 (en) 2016-06-08
WO2015017710A1 (en) 2015-02-05
JP2021113219A (ja) 2021-08-05
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
PT3027642T (pt) 2020-10-30
PE20160189A1 (es) 2016-05-06
EA037355B1 (ru) 2021-03-17
KR102376451B1 (ko) 2022-03-23
MX2019012848A (es) 2019-11-28
KR20240000642A (ko) 2024-01-02
KR20160038896A (ko) 2016-04-07
CY1123836T1 (el) 2022-03-24
TWI648401B (zh) 2019-01-21
CR20160097A (es) 2016-07-29
US20160168213A1 (en) 2016-06-16
JP2016532690A (ja) 2016-10-20
HUE050630T2 (hu) 2020-12-28
JP2023116723A (ja) 2023-08-22
CA2918624A1 (en) 2015-02-05
CA2918624C (en) 2024-02-13
US20210079051A1 (en) 2021-03-18
MX369152B (es) 2019-10-30
EA202092386A1 (ru) 2021-04-30
PL3027642T3 (pl) 2021-01-11
ZA201600523B (en) 2024-10-30
AP2016009011A0 (en) 2016-01-31
US20180079790A1 (en) 2018-03-22
EP3027642B1 (en) 2020-08-19
CN105980400A (zh) 2016-09-28
DK3027642T3 (da) 2020-11-02
HK1225738A1 (en) 2017-09-15
EP3763734A1 (en) 2021-01-13
EA201690297A1 (ru) 2016-06-30
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
CN113527512A (zh) 2021-10-22
UY35686A (es) 2015-01-30
PH12016500208A1 (en) 2016-04-25
NZ754961A (en) 2022-04-29
UA116665C2 (uk) 2018-04-25
MX2016001164A (es) 2016-07-26
AR097181A1 (es) 2016-02-24
MX387211B (es) 2025-03-18
IL243749A0 (en) 2016-04-21
JP2019178132A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
IL243749B (en) Growth differentiation factor templates 15
IL233725A0 (en) Growth and differentiation factor 15 (gdf-15) polypeptides
IL235832A0 (en) Fibroblastic growth factor 21 proteins
GB2530923B (en) Smart shaker room
ZA201603218B (en) Afucosylated anti-fgfr2iiib antibodies
GB201302597D0 (en) Novel Synthetic Proteins
KR101391404B9 (ko) 골신장기
SI3016977T1 (sl) Humana protitelesa proti IL-32
ZA201508035B (en) Epidermal growth factor receptor antibody
PL3511466T3 (pl) Zwoje w kształcie symbolu nieskończoności
GB201312513D0 (en) 2 4 1 Technology
GB2515170B (en) Horticultural preparation or formulation
GB201304642D0 (en) 02 Planter
GB201322568D0 (en) Taggstar 1
GB201308820D0 (en) Part 3 under
AU350588S (en) Joiner (1)
AU350589S (en) Joiner (2)
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270